Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
Femasys Inc. (FEMY)
Company Research
Source: GlobeNewswire
ATLANTA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Israeli Medical Device Division of the Ministry of Health’s (AMAR) approvals for the FemaSeed® Intratubal Insemination product for female infertility treatment and two diagnostic devices, FemVue® for tubal evaluation and FemCerv® for cervical cancer detection. “We remain committed to our mission of delivering critically important technological advancements to women globally, with Israel now added to our expanding reach.” stated Kathy Lee-Sepsick, Femasys’ CEO. “FemaSeed, along with our entire suite of products, has been developed to provide women with better, lower-cost and more accessible options. We remain focused on commercial execution in the U.S. and select other countries as we continue
Show less
Read more
Impact Snapshot
Event Time:
FEMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FEMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FEMY alerts
High impacting Femasys Inc. news events
Weekly update
A roundup of the hottest topics
FEMY
News
- Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic DeviceGlobeNewswire
- Femasys (NASDAQ:FEMY) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=FEMY&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> frMarketBeat
- Femasys (NASDAQ:FEMY) is now covered by analysts at Laidlaw. They set a "buy" rating and a $6.50 price target on the stock.MarketBeat
- Femasys GAAP EPS of -$0.10, revenue of $729M [Seeking Alpha]Seeking Alpha
- Femasys Announces Third Quarter Financial Results for 2025 [Yahoo! Finance]Yahoo! Finance
FEMY
Sec Filings
- 12/18/25 - Form 8-K
- 12/10/25 - Form EFFECT
- 12/4/25 - Form S-3/A
- FEMY's page on the SEC website